In summary, this study will study the potential therapeutical effects of denosumab (RANKL inhibitior) on patients with sarcopenia and underlying osteoporosis, which will be crucial given the aging population and expected increase in disease numbers. The gene discussed is TNFSF11; the disease is sarcopenia.